Crown Bioscience Launches New Interactive Feature for XenoBase™ In Vitro Models

USA - English

• USA - Français
• USA - Deutsch

SANTA CLARA, Calif., Sept. 22, 2016 /PRNewswire/ -- Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has published a further enriched version of its XenoBase, the world's first online database collating cell line and cell line derived xenograft model data.

The newly added module complements the existing database's powerful search options of publicly profiled data (gene expression, copy number and mutation) as well as proprietary histopathology, in vivo pharmacology, tumor growth and molecular pathology data for over 200 validated cell line derived xenograft models and for more than 1,000 tumor cell lines.

Thanks to the new XenoBase feature, users will now be able to directly search and interact with dose response curves and IC₅₀ data for over 290 cell lines, providing the ability to rapidly review and select the most appropriate model for their in vitro studies.

"We've come a long way since the release of our first version of XenoBase," said Qian Shi, Ph.D., vice president of cancer pharmacology and in vitro cancer biology at CrownBio. "Getting instant access to in vitro pharmacology data linked to in vivo data from the corresponding cell line derived xenograft in one comprehensive and easy-to-browse platform means clients will be able to plan their studies with an end-to-end solution in mind."

Registered XenoBase users can already take advantage of the new feature, while new clients can simply send a request to register to start using the service from the company website.

"Our experienced bioinformatics and operation teams have made great strides to enhance our database functionalities. This demonstrates our continued commitment towards achieving our mission to make clients' drug discovery research programs faster and more efficient," said Laurie Heilmann, senior vice president of global strategy, marketing and business development at CrownBio.

For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit www.crownbio.com.

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.

Logo - http://photos.prnewswire.com/prnh/20160405/351602LOGO

SOURCE Crown Bioscience Inc.

Related Links

http://www.crownbio.com